Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-1692.96%
operating margin TTM
-1765.01%
revenue TTM
18.21 Million
revenue per share TTM
0.32$
valuation ratios | |
|---|---|
| pe ratio | -0.85 |
| peg ratio | 0.31 |
| price to book ratio | 0.84 |
| price to sales ratio | 6.29 |
| enterprise value multiple | -0.93 |
| price fair value | 0.84 |
profitability ratios | |
|---|---|
| gross profit margin | 90.89% |
| operating profit margin | -1765.01% |
| pretax profit margin | -1692.96% |
| net profit margin | -1692.96% |
| return on assets | -54.38% |
| return on equity | -73.89% |
| return on capital employed | -63.8% |
liquidity ratios | |
|---|---|
| current ratio | 6.44 |
| quick ratio | 6.44 |
| cash ratio | 5.80 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 3,023.27 |
| cash conversion cycle | -3,023.27 |
| receivables turnover | 0.00 |
| payables turnover | 0.12 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.36 |
| debt equity ratio | 0.66 |
| long term debt to capitalization | 0.18 |
| total debt to capitalization | 0.40 |
| interest coverage | -52.15 |
| cash flow to debt ratio | -1.37 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.05 |
| cash per share | 1.42 |
| operating cash flow per share | -1.01 |
| free cash flow operating cash flow ratio | 1.04 |
| cash flow coverage ratios | -1.37 |
| short term coverage ratios | -18.94 |
| capital expenditure coverage ratio | -25.51 |
Frequently Asked Questions
When was the last time TScan Therapeutics, Inc. (NASDAQ:TCRX) reported earnings?
TScan Therapeutics, Inc. (TCRX) published its most recent earnings results on 12-11-2025.
What is TScan Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. TScan Therapeutics, Inc. (NASDAQ:TCRX)'s trailing twelve months ROE is -73.89%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. TScan Therapeutics, Inc. (TCRX) currently has a ROA of -54.38%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did TCRX's net profit margin stand at?
TCRX reported a profit margin of -1692.96% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is TCRX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 6.44 in the most recent quarter. The quick ratio stood at 6.44, with a Debt/Eq ratio of 0.66.